Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Free Cash Flow: 2017-2025

Historic Free Cash Flow for Dianthus Therapeutics (DNTH) over the last 6 years, with Sep 2025 value amounting to -$30.6 million.

  • Dianthus Therapeutics' Free Cash Flow fell 43.53% to -$30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.6 million, marking a year-over-year decrease of 74.92%. This contributed to the annual value of -$78.3 million for FY2024, which is 111.75% down from last year.
  • Latest data reveals that Dianthus Therapeutics reported Free Cash Flow of -$30.6 million as of Q3 2025, which was down 27.66% from -$23.9 million recorded in Q2 2025.
  • Dianthus Therapeutics' Free Cash Flow's 5-year high stood at $16.4 million during Q3 2022, with a 5-year trough of -$30.6 million in Q3 2025.
  • Over the past 3 years, Dianthus Therapeutics' median Free Cash Flow value was -$15.0 million (recorded in 2024), while the average stood at -$17.9 million.
  • As far as peak fluctuations go, Dianthus Therapeutics' Free Cash Flow skyrocketed by 72.02% in 2023, and later crashed by 206.08% in 2024.
  • Quarterly analysis of 4 years shows Dianthus Therapeutics' Free Cash Flow stood at -$8.9 million in 2022, then plummeted by 33.60% to -$11.9 million in 2023, then crashed by 131.58% to -$27.5 million in 2024, then plummeted by 43.53% to -$30.6 million in 2025.
  • Its last three reported values are -$30.6 million in Q3 2025, -$23.9 million for Q2 2025, and -$27.7 million during Q1 2025.